Fluvastatin: Clinical and safety profile

Drugs

Volumn 64, Issue 12, 2004, Pages 1305-1323

  Corsini, Alberto ^a   Jacobson, Terry A ^b   Ballantyne, Christie M ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIFUNGAL AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM ANTAGONIST; CARDIOVASCULAR AGENT; CERIVASTATIN; COUMARIN; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PREDNISONE; ROSUVASTATIN; SIMVASTATIN; UNINDEXED DRUG; WARFARIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG SAFETY; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INTIMA; ISCHEMIC HEART DISEASE; MYOPATHY; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POSITRON EMISSION TOMOGRAPHY; RESTENOSIS; REVIEW; RHABDOMYOLYSIS;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; FATTY ACIDS, MONOUNSATURATED; HUMANS; INDOLES; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT;

EID: 3142687675     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464120-00004     Document Type: Review

References (101)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov 19; 344 (8934): 1383-9
2. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 Nov 16; 333 (20): 1301-7
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 Oct 3; 335: 1001-9
4. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 Nov 5; 339 (19): 1349-57
5. Downs JR, Clearfield M, Weis S, et al., for the Air Force/Texas Coronary Atherosclerosis Prevention Study Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998 May 27; 279 (20): 1615-22
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul 6; 360 (9326): 7-22
7. Serruys PWJC, de Feyter P, Macaya C, et al., for the Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized, placebo-controlled trial. JAMA 2002 Jun 26; 287 (24): 3215-22
8. Shepherd J, Blauw GJ, Murphy MBG, et al., for the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 Nov 23; 360 (9346): 1623-30
9. Holdaas H, Fellström B, Jardine AG, et al., on behalf of the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003 Jun 14; 361 (9374): 2024-31
10. Sever PS, Dahlöf B, Poulter NR, et al., for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. Lancet 2003 Apr 5; 361 (9364): 1149-58
11. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999 Dec 22-29; 282 (24): 2340-46
12. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007
13. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003 Mar 10; 163 (5): 553-64
14. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001 Nov 5; 175 (9): 486-9
15. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis [letter]. N Engl J Med 2002 Feb 14; 346 (7): 539-40
16. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2 (5): 205-7
17. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003 Apr 2; 289 (13): 1681-90
18. SoRelle R. Baycol withdrawn from market. Circulation 2001 Aug 21; 104 (8): E9015-6
19. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001 Sep; 35 (9): 1096-107
20. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995 Aug 1; 52 (15): 1639-43
21. Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 1996 Oct; 24 (5): 461-73
22. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999 Dec; 84 (3): 413-28
23. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002 Feb; 36 (2): 288-95
24. Prueksaritanont T, Subramanian R, Fang X. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002; 30: 505-12
25. Kyrklund C, Backman JT, Kivisto KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69: 340-5
26. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301: 1042-51
27. Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122-9
28. Farnier M, Bortolini M, Salko T, et al. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol 2003 Jan 15; 91 (2): 238-40
29. Bellosta S, Ferri N, Bernini F, et al. Non-lipid-related effects of statins. Ann Med 2000 Apr; 32 (3): 164-76
30. Comparato C, Altana C, Bellosta S, et al. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Nutr Metab Cardiovasc Dis 2001 Oct; 11 (5): 328-43
31. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990 Feb 1; 343 (6257): 425-30
32. Corsini A, Pazzucconi F, Arnaboldi L, et al. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 1998 May; 31 (5): 773-8
33. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998 Apr; 137 Suppl.: S101-9
34. Bellosta S, Ferri N, Arnaboldi L, et al. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000 Apr; 23 Suppl. 2: B72-8
35. Ridker PM, Rifai N, Pfeffer MA, et al., for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999 Jul 20; 100 (3): 230-35
36. Shovman O, Levy Y, Gilburd B, et al. Antiinflammatory and immunomodulatory properties of statins. Immunol Res 2002; 25 (3): 271-85
37. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001 Nov; 21 (11): 1712-9
38. Ikeda U, Shimada K. Pleiotropic effects of statins on the vascular tissue. Curr Drug Targets Cardiovasc Haematol Disord 2001 Jun; 1 (1): 51-8
39. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998 May 27; 279 (20): 1643-50
40. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 1996 Jan 13; 347 (8994): 102-3
41. Soma MR, Donetti E, Parolini C, et al. HMG CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993 Apr; 13 (4): 571-8
42. Baetta R, Camera M, Comparato C, et al. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2002 Apr 1; 22 (4): 692-8
43. Sakaeda T, Takara K, Kakumoto M, et al. Simvastatin and lovastatin, but not pravastatin, interact with MDR1. J Pharm Pharmacol 2002 Mar; 54 (3): 419-23
44. Rosenson RS, Tangney CC, Schaefer EJ. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis 2001 Apr; 155 (2): 463-6
45. Sindermann JR, Fan L, Weigel KA, et al. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Atherosclerosis 2000 Jun; 150 (2): 331-41
46. Yasunari K, Maeda K, Minami M, et al. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 2001 Jun; 21 (6): 937-42
47. Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000; 7 (3): 138-44
48. Tesfamariam B, Frohlich BH, Gregg RE. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. J Cardiovasc Pharmacol 1999 Jul; 34 (1): 95-101
49. Ridker PM, Rifai N, Pfeffer MA, et al., for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998 Sep 1; 98 (9): 839-44
50. Basso F, Lowe GD, Rumley A, et al. Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland Coronary Prevention Study (WOSCOPS). Arterioscler Thromb Vasc Biol 2002 Apr 1; 22 (4): 599-604
51. Fischer V, Johnason L, Heitz F, et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999 Mar; 27 (3): 410-6
52. Tse FL, Nickerson DF, Yardley WS. Binding of fluvastatin to blood cells and plasma proteins. J Pharm Sci 1993 Sep; 82 (9): 942-7
53. Barilla D, Prasad P, Hubert M, et al. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol® XL. Biopharm Drug Dispos 2004 Mar; 25 (2): 51-9
54. Sabia H, Prasad P, Smith HT, et al. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolaemia. J Cardiovasc Pharmacol 2001 May; 37 (5): 502-11
55. Ballantyne CM, Pazzucconi F, Pintó X, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther 2001 Feb; 23 (2): 177-92
56. Bruckert E, Liévre M, Giral P, et al. Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am J Geriatr Cardiol 2003 Jul-Aug; 12 (4): 225-31
57. Winkler K, Abletshauser C, Hoffmann MM, et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab 2002 Dec; 87 (12): 5485-90
58. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997 Aug 1; 80 (3): 278-86
59. Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999 Feb 16; 99 (6): 736-43
60. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999 May; 144 (1): 263-70
61. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999 Jan; 20 (1): 58-69
62. Liem AH, van Boven AJ, Veeger NJ, et al., and the FLuvastatin On Risk Diminishment after Acute Myocardial Infarction Study Group. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 2002 Dec; 23 (24): 1931-7
63. Lefkovits J, Topol FJ. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Prog Cardiovasc Dis 1997 Sep-Oct; 40 (2): 141-58
64. Kleemann A, Eckert S, von Eckardstein A, et al., and the CLAPT Study. Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA: the cholesterol lowering atherosclerosis PTCA trial (CLAPT). Eur Heart J 1999 Oct; 20 (19): 1393-406
65. Weintraub WS, Boccuzzi SJ, Klein JL, et al., and the Lovastatin Restenosis Trial Study Group. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994 Nov; 331 (20): 1331-7
66. Bertrand ME, McFadden EP, Fruchart JC, et al., for the PREDICT Trial Investigators. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1997 Oct; 30 (4): 863-9
67. Benghozi R, Bortolini M, Jia Y, et al. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002 Jan 15; 89 (2): 231-3
68. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001 Jul-Aug; 35 (7-8): 908-17
69. Jacobson TA. Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. Expert Opin Drug Saf 2003 May; 2 (3): 269-86
70. Jardine A, Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. J Clin Pharm Ther 1999 Dec; 24 (6): 397-408
71. Foldes K, Maklary E, Vargha P, et al. Effect of diet and fluvastatin treatment on the serum lipid profile of kidney transplant, diabetic recipients: a 1-year follow up. Transpl Int 1998; 11 Suppl. 1: S65-8
72. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996 Dec 15; 62 (11): 1559-64
73. Holdaas H, Hartmann A, Stenstrom J, et al. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995 Jul 13; 76 (2): 102A-6A
74. Holdaas H, Jardine AG, Wheeler DC, et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int 2001 Nov; 60 (5): 1990-7
75. Malyszko J, Malyszko JS, Brzosko S, et al. Effects of fluvastatin on homocysteine and serum lipids in kidney allograft recipients. Ann Transplant 2002; 7 (1): 52-4
76. Gomez G, Alvarez ML, Errasti P, et al. Fluvastatin in the treatment of hypercholesterolemia in renal transplantation. Transplant Proc 1999 Sep; 31 (6): 2326-7
77. Samuelsson O, Attman PO, Knight-Gibson C, et al. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. Am J Kidney Dis 2002 Jan; 39 (1): 67-75
78. Ichihara A, Hayashi M, Ryuzaki M, et al. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002 Aug; 17 (8): 1513-7
79. Hunninghake DB, Davidson M, Knapp HR, et al., and the Fluvastatin Study Group. An extended-release formulation of fluvastatin 80mg shows greater efficacy, with comparable tolerability, versus immediate-release fluvastatin 40mg for once-daily treatment of primary hypercholesterolaemia. Br J Cardiol 2002 Sep; 9 (8): 469-75
80. Olsson AG, Pauciullo P, Soska V, et al. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolaemia: a randomized trial. Clin Ther 2001 Jan; 23 (1): 45-61
81. Corsini A. Fluvastatin: effects beyond cholesterol-lowering. J Cardiovasc Pharmacol Ther 2000 Jul; 5 (3): 161-75
82. Kimura M, Kurose I, Russell J, et al. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 1997 Aug; 17 (8): 1521-6
83. Ogata Y, Takahashi M, Takeuchi K, et al. Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy. J Cardiovasc Pharmacol 2002 Dec; 40 (6): 907-15
84. Ito T, Ikeda U, Shimpo M, et al. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc Drugs Ther 2002 Mar; 16 (2): 121-6
85. Corsini A, Pazzucconi F, Pfister P, et al. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet 1996 Dec 7; 348 (9041): 1584
86. Mussoni L, Banfi C, Sironi L, et al. Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. Thromb Haemost 2000 Jul; 84 (1): 59-64
87. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001 Jan; 154 (1): 87-96
88. Yasuhara M, Suzumura K, Tanaka K, et al. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits. Biol Pharm Bull 2000 May; 23 (5): 570-4
89. Bandoh T, Mitani H, Niihashi M, et al. Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J Cardiovasc Pharmacol 2000 Jan; 35 (1): 136-44
90. Hussein O, Schlezinger S, Rosenblat M, et al. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997 Jan 3; 128 (1): 11-8
91. Gheith OA, Sobh MA, Mohamed KE, et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron 2002 Aug; 91 (4): 612-9
92. Inoue T, Hayashi M, Takayanagi K, et al. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. Atherosclerosis 2002 Feb; 160 (2): 369-76
93. Hausberg M, Kosch M, Stam F, et al. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int 2001 Apr; 59 (4): 1473-9
94. Hedblad B, Wikstrand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001 Apr 3; 103 (13): 1721-6
95. Haak E, Abletshauser C, Weber S, et al. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis 2001 Apr; 155 (2): 395-401
96. Eichstädt HW, Abletshauser CB, Störk T, et al. Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease. J Cardiovasc Pharmacol 2000 May; 345 (5): 735-40
97. Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med 2000; 48 (3): 183-9
98. Guethlin M, Kasel AM, Coppenrath K, et al. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 1999 Feb 2; 99 (4): 474, 475-81
99. Ridker PM. Connecting the role of C-reactive protein and statins in cardiovascular disease. Clin Cardiol 2003 Apr; 26 (4 Suppl. 3): III39-44
100. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002 Nov 14; 347 (20): 1557-65
101. Chi DS, Jin FX, Yang SG, et al. Effects of fluvastatin on the levels of C-reactive protein and lipids in patients with hyperlipidemia [in Chinese]. Di Yi Jun Yi Da Xue Xue Bao 2002 Dec; 22 (12): 1109-11